Literature DB >> 24957864

Genetic predisposition to schizophrenia associated with increased use of cannabis.

R A Power1, K J H Verweij2, M Zuhair3, G W Montgomery4, A K Henders4, A C Heath5, P A F Madden5, S E Medland4, N R Wray6, N G Martin4.   

Abstract

Cannabis is the most commonly used illicit drug worldwide. With debate surrounding the legalization and control of use, investigating its health risks has become a pressing area of research. One established association is that between cannabis use and schizophrenia, a debilitating psychiatric disorder affecting ~1% of the population over their lifetime. Although considerable evidence implicates cannabis use as a component cause of schizophrenia, it remains unclear whether this is entirely due to cannabis directly raising risk of psychosis, or whether the same genes that increases psychosis risk may also increase risk of cannabis use. In a sample of 2082 healthy individuals, we show an association between an individual's burden of schizophrenia risk alleles and use of cannabis. This was significant both for comparing those who have ever versus never used cannabis (P=2.6 × 10(-4)), and for quantity of use within users (P=3.0 × 10(-3)). Although directly predicting only a small amount of the variance in cannabis use, these findings suggest that part of the association between schizophrenia and cannabis is due to a shared genetic aetiology. This form of gene-environment correlation is an important consideration when calculating the impact of environmental risk factors, including cannabis use.

Entities:  

Mesh:

Year:  2014        PMID: 24957864      PMCID: PMC4382963          DOI: 10.1038/mp.2014.51

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  41 in total

1.  Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.

Authors:  Stanley Zammit; Peter Allebeck; Sven Andreasson; Ingvar Lundberg; Glyn Lewis
Journal:  BMJ       Date:  2002-11-23

2.  Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.

Authors:  Louise Arseneault; Mary Cannon; Richie Poulton; Robin Murray; Avshalom Caspi; Terrie E Moffitt
Journal:  BMJ       Date:  2002-11-23

3.  Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences.

Authors:  A Y Tien; J C Anthony
Journal:  J Nerv Ment Dis       Date:  1990-08       Impact factor: 2.254

4.  Transitions in drinking in adolescent females: evidence from the Missouri adolescent female twin study.

Authors:  K K Bucholz; A C Heath; P A Madden
Journal:  Alcohol Clin Exp Res       Date:  2000-06       Impact factor: 3.455

5.  Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies.

Authors:  Patrick F Sullivan; Kenneth S Kendler; Michael C Neale
Journal:  Arch Gen Psychiatry       Date:  2003-12

6.  The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.

Authors:  Deepak Cyril D'Souza; Edward Perry; Lisa MacDougall; Yola Ammerman; Thomas Cooper; Yu-Te Wu; Gabriel Braley; Ralitza Gueorguieva; John Harrison Krystal
Journal:  Neuropsychopharmacology       Date:  2004-08       Impact factor: 7.853

7.  Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample.

Authors:  Michael T Compton; Andrew C Furman; Nadine J Kaslow
Journal:  Schizophr Res       Date:  2004-11-01       Impact factor: 4.939

8.  Motivations that maintain substance use among individuals with psychotic disorders.

Authors:  Catherine Spencer; David Castle; Patricia T Michie
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

Review 9.  Causal association between cannabis and psychosis: examination of the evidence.

Authors:  Louise Arseneault; Mary Cannon; John Witton; Robin M Murray
Journal:  Br J Psychiatry       Date:  2004-02       Impact factor: 9.319

10.  Genome-wide association analysis identifies 13 new risk loci for schizophrenia.

Authors:  Stephan Ripke; Colm O'Dushlaine; Kimberly Chambert; Jennifer L Moran; Anna K Kähler; Susanne Akterin; Sarah E Bergen; Ann L Collins; James J Crowley; Menachem Fromer; Yunjung Kim; Sang Hong Lee; Patrik K E Magnusson; Nick Sanchez; Eli A Stahl; Stephanie Williams; Naomi R Wray; Kai Xia; Francesco Bettella; Anders D Borglum; Brendan K Bulik-Sullivan; Paul Cormican; Nick Craddock; Christiaan de Leeuw; Naser Durmishi; Michael Gill; Vera Golimbet; Marian L Hamshere; Peter Holmans; David M Hougaard; Kenneth S Kendler; Kuang Lin; Derek W Morris; Ole Mors; Preben B Mortensen; Benjamin M Neale; Francis A O'Neill; Michael J Owen; Milica Pejovic Milovancevic; Danielle Posthuma; John Powell; Alexander L Richards; Brien P Riley; Douglas Ruderfer; Dan Rujescu; Engilbert Sigurdsson; Teimuraz Silagadze; August B Smit; Hreinn Stefansson; Stacy Steinberg; Jaana Suvisaari; Sarah Tosato; Matthijs Verhage; James T Walters; Douglas F Levinson; Pablo V Gejman; Kenneth S Kendler; Claudine Laurent; Bryan J Mowry; Michael C O'Donovan; Michael J Owen; Ann E Pulver; Brien P Riley; Sibylle G Schwab; Dieter B Wildenauer; Frank Dudbridge; Peter Holmans; Jianxin Shi; Margot Albus; Madeline Alexander; Dominique Campion; David Cohen; Dimitris Dikeos; Jubao Duan; Peter Eichhammer; Stephanie Godard; Mark Hansen; F Bernard Lerer; Kung-Yee Liang; Wolfgang Maier; Jacques Mallet; Deborah A Nertney; Gerald Nestadt; Nadine Norton; Francis A O'Neill; George N Papadimitriou; Robert Ribble; Alan R Sanders; Jeremy M Silverman; Dermot Walsh; Nigel M Williams; Brandon Wormley; Maria J Arranz; Steven Bakker; Stephan Bender; Elvira Bramon; David Collier; Benedicto Crespo-Facorro; Jeremy Hall; Conrad Iyegbe; Assen Jablensky; Rene S Kahn; Luba Kalaydjieva; Stephen Lawrie; Cathryn M Lewis; Kuang Lin; Don H Linszen; Ignacio Mata; Andrew McIntosh; Robin M Murray; Roel A Ophoff; John Powell; Dan Rujescu; Jim Van Os; Muriel Walshe; Matthias Weisbrod; Durk Wiersma; Peter Donnelly; Ines Barroso; Jenefer M Blackwell; Elvira Bramon; Matthew A Brown; Juan P Casas; Aiden P Corvin; Panos Deloukas; Audrey Duncanson; Janusz Jankowski; Hugh S Markus; Christopher G Mathew; Colin N A Palmer; Robert Plomin; Anna Rautanen; Stephen J Sawcer; Richard C Trembath; Ananth C Viswanathan; Nicholas W Wood; Chris C A Spencer; Gavin Band; Céline Bellenguez; Colin Freeman; Garrett Hellenthal; Eleni Giannoulatou; Matti Pirinen; Richard D Pearson; Amy Strange; Zhan Su; Damjan Vukcevic; Peter Donnelly; Cordelia Langford; Sarah E Hunt; Sarah Edkins; Rhian Gwilliam; Hannah Blackburn; Suzannah J Bumpstead; Serge Dronov; Matthew Gillman; Emma Gray; Naomi Hammond; Alagurevathi Jayakumar; Owen T McCann; Jennifer Liddle; Simon C Potter; Radhi Ravindrarajah; Michelle Ricketts; Avazeh Tashakkori-Ghanbaria; Matthew J Waller; Paul Weston; Sara Widaa; Pamela Whittaker; Ines Barroso; Panos Deloukas; Christopher G Mathew; Jenefer M Blackwell; Matthew A Brown; Aiden P Corvin; Mark I McCarthy; Chris C A Spencer; Elvira Bramon; Aiden P Corvin; Michael C O'Donovan; Kari Stefansson; Edward Scolnick; Shaun Purcell; Steven A McCarroll; Pamela Sklar; Christina M Hultman; Patrick F Sullivan
Journal:  Nat Genet       Date:  2013-08-25       Impact factor: 38.330

View more
  54 in total

1.  Perspective: Be clear about the real risks.

Authors:  Matthew Hill
Journal:  Nature       Date:  2015-09-24       Impact factor: 49.962

2.  Prescribing medical cannabis in Canada: Are we being too cautious?

Authors:  Stephanie Lake; Thomas Kerr; Julio Montaner
Journal:  Can J Public Health       Date:  2015-04-30

3.  Genetic and Environmental Contributions to the Association Between Cannabis Use and Psychotic-Like Experiences in Young Adult Twins.

Authors:  Ragnar Nesvåg; Ted Reichborn-Kjennerud; Nathan A Gillespie; Gun Peggy Knudsen; Jørgen G Bramness; Kenneth S Kendler; Eivind Ystrom
Journal:  Schizophr Bull       Date:  2017-05-01       Impact factor: 9.306

4.  Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006-2015.

Authors:  Bridget Maloney-Hall; Sarah C Wallingford; Sarah Konefal; Matthew M Young
Journal:  Health Promot Chronic Dis Prev Can       Date:  2020-06       Impact factor: 3.240

Review 5.  Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Authors:  Marc W Manseau; Donald C Goff
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

6.  Association Between Substance Use Disorder and Polygenic Liability to Schizophrenia.

Authors:  Sarah M Hartz; Amy C Horton; Mary Oehlert; Caitlin E Carey; Arpana Agrawal; Ryan Bogdan; Li-Shiun Chen; Dana B Hancock; Eric O Johnson; Carlos N Pato; Michele T Pato; John P Rice; Laura J Bierut
Journal:  Biol Psychiatry       Date:  2017-06-06       Impact factor: 13.382

Review 7.  Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations.

Authors:  Benedikt Fischer; Cayley Russell; Pamela Sabioni; Wim van den Brink; Bernard Le Foll; Wayne Hall; Jürgen Rehm; Robin Room
Journal:  Am J Public Health       Date:  2017-06-23       Impact factor: 9.308

8.  [On the legalization debate of non-medical cannabis consumption : Position paper of the German Association for Psychiatry, Psychotherapy and Psychosomatics].

Authors:  U Havemann-Reinecke; E Hoch; U W Preuss; F Kiefer; A Batra; G Gerlinger; I Hauth
Journal:  Nervenarzt       Date:  2017-03       Impact factor: 1.214

9.  Multi-Polygenic Score Approach to Identifying Individual Vulnerabilities Associated With the Risk of Exposure to Bullying.

Authors:  Tabea Schoeler; Shing Wan Choi; Frank Dudbridge; Jessie Baldwin; Lauren Duncan; Charlotte M Cecil; Esther Walton; Essi Viding; Eamon McCrory; Jean-Baptiste Pingault
Journal:  JAMA Psychiatry       Date:  2019-07-01       Impact factor: 21.596

10.  Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed.

Authors:  Margaret Haney; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2015-08-19       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.